Cosmos Health Inc. (COSM) analyst actions
COSM analyst actions moved a median of +1.41% by the close. Rating and price-target actions on COSM in the public-source dataset. Wires and filings carry few rating actions, so this list is sparse by nature — the hub's by-event-type table holds the measured analyst base rates. Back to the COSM overview →
11 measured COSM analyst action events.
| Middle 50% of COSM analyst action reactions | +0.15% to +2.96% |
|---|---|
| Median reaction (to close) | +1.41% |
| Measured reactions | 10 |
Half of the 10 COSM analyst action events with a measured close landed between +0.15% and +2.96%; 70% closed up.
| Date | Headline | Event | 5-min | To close |
|---|---|---|---|---|
| Noble Capital Markets Initiates Equity Research Coverage on Cosmos Health with Outperform Rating and $1.40 Price Target | Press release | +2.48% | +3.75% | |
| Cosmos Health Receives Updated Zacks Research Report: 2026 Revenue Forecast Raised to $103.2 Million, EPS Outlook Upgraded to Positive Territory, and $4.50 Valuation Reaffirmed | Press release | -0.20% | -2.47% | |
| Cosmos Health Announces Initiation of Analyst Coverage with $4.50 Valuation by Zacks Small-Cap Research | Press release | +1.85% | -1.83% | |
| Cosmos Health Further Expands Facility Upgrades Program at Cana Laboratories and Signs 5-Year Contract Manufacturing Agreement with Pharmex for 1.5 Million Bottles of the Antiseptic Drug AMBITASOL 1L | Press release | +2.45% | -0.09% | |
| Taglich Brothers Releases Updated Coverage on Cosmos Health: Projects Positive EPS for 2025 and Sets $3 Price Target, Nearly 300% Above Current Share Price | Press release | +0.16% | +1.95% | |
| Taglich Brothers Publishes Updated Coverage Report on Cosmos Health; Maintains Price Target of $4, Nearly 300% Above Current Share Price | Press release | +1.39% | +6.53% | |
| Cosmos Health's Cana Laboratories Completes Facility Upgrades and Secures Contract Manufacturing Agreement with Provident Pharmaceuticals for 4.32 Million Vials of DE3-SOLE | Press release | +1.06% | +2.99% | |
| Cosmos Health's Cana Laboratories Completes Facility Upgrades and Secures Contract Manufacturing Agreement with Provident Pharmaceuticals for 4.32 Million Vials of DE3-SOLE | Press release | — | — | |
| Taglich Brothers Initiates Coverage of Cosmos Health Inc. | Press release | +0.00% | +0.88% | |
| Taglich Brothers Publishes First Coverage Report on Cosmos Health with a Price Target of $4, a Nearly Five-Fold Increase from Current Share Price | Press release | +6.63% | +0.88% | |
| Taglich Brothers Initiates Coverage of Cosmos Health Inc. | Press release | -0.94% | +2.86% |
More COSM: earnings → · SEC filings → · COSM overview →
Other Healthcare names and their analyst actions
| Ticker | Events | Median 30-min | % positive |
|---|---|---|---|
| TERRASCENT CORP (TRSSF) | 453 | -0.04% | 44% |
| Glaukos Corporation (GKOS) | 452 | +0.04% | 51% |
| ROCHE HOLDING LTD S/ADR (RHHBY) | 449 | +0.03% | 52% |
| CareDx, Inc. (CDNA) | 443 | -0.11% | 47% |
Same sector, same measurement: percent move vs. the price at the news timestamp, read at 30 minutes. Sample sizes differ, so the medians are comparable but the confidence behind them is not. These are each name’s all-news baseline, not its analyst actions — that is what the link opens.